22 completed, 14 unknown, 8 recruiting, 4 not yet recruiting. 26 Phase 2, 9 Phase 4, 8 Not applicable, 7 Phase 3, 5 Phase 1.
Follow Thymalfasin: new trials by email Literature Review of Thymalfasin trials Research Report on Thymalfasin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection Ulinastatin and Thymalfasin, Ulinastatin - Aortic Aneurysm and Dissection | Not applicable | Not yet recruiting | Nanjing Medical University | 300 | 2027-12-31 | 2026-02-02 |
| Thymalfasin Combined With Chemotherapy and Immunotherapy in TNBC Neoadjuvant Treatment Thymalfasin - Breast Cancer, TNBC - Triple-Negative Breast Cancer | Phase 2 | Not yet recruiting | Fudan University | 572 | 2026-11-08 | 2026-10-20 |
| Thymalfasin for Immune Recovery in Adults With Sepsis Thymalfasin (Thymosin alpha 1, Ta1) - Sepsis, Immunosuppression | Not applicable | Recruiting | Shanghai Zhongshan Hospital | 60 | 2026-10-06 | 2026-10-08 |
| Study of Adebrelimab Combined With Thymalfasin and Chemotherapy for Neoadjuvant Treatment of Esophageal Cancer Adebrelimab, Thymalfasin, Chemotherapy - Esophageal Cancer | Phase 2 | Not yet recruiting | The Affiliated Hospital of Putian University | 31 | 2026-08-30 | 2026-08-21 |
| Thymosin-α1 for Recurrent Implantation Failure Thymosin Alpha1, Placebo Control - Recurrent Implantation Faliure | Phase 2 / Phase 3 | Recruiting | Fakih IVF Fertility Center | 136 | 2026-02-11 | 2026-10-15 |
| "Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer" Thymalfasin (Thymosin alpha 1, Ta1), Regorafenib (BAY 73-4506), Tislelizumab (BGB-A317) - MCRC | Phase 2 | Recruiting | Beijing Friendship Hospital | 52 | 2025-02-11 | 2025-02-17 |
| Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine Thymalfasin (Thymosin alpha 1, Ta1) - Vaccine Response, COVID-19 Vaccine | Phase 1 | Recruiting | The Methodist Hospital Research Institute | 75 | 2024-12-02 | 2026-07-16 |
| Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC Thymosin Alpha 1, Tislelizumab, Platinum-doublet chemotherapy - Resectable Non-Small-Cell Lung Cancer | Not applicable | Unknown | Xuanwu Hospital, Beijing | 40 | 2024-10-15 | 2024-09-23 |
| Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological Tumors Thymalfasin for injection in combination with Recombinant Human Interleukin-2 Injections, Recombinant Human Interleukin-2 Injections - Hematological Malignancy, Lymphocytopenia | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 50 | 2024-09-01 | 2024-09-19 |
| Immuno-effect of Tα1 for Stage I NSCLC Thymosin Alpha1 - Non Small Cell Lung Cancer | Not applicable | Unknown | Yousheng Mao | 40 | 2024-06-30 | 2024-09-19 |
| Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma Serplulimab, thymalfasin, Oxaliplatin - Gastric Cancer, Esophagogastric Junction Adenocarcinoma | Phase 2 | Recruiting | Zekuan Xu | 30 | 2024-06-14 | 2026-03-03 |
| Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer capecitabine, tislelizumab, thymalfasin - Locally Advanced Rectal Cancer | Phase 2 | Active not recruiting | Beijing Friendship Hospital | 20 | 2024-01-03 | 2025-04-02 |
| Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for Locally Advanced Mid-low Rectal Cancer Thymalfasin - Colorectal Neoplasms | Completed | Beijing Friendship Hospital | 47 | 2023-09-20 | 2026-06-18 | |
| Thymosin Alpha-1 for irAE Secondary to ICIs Thymosin Alpha1, Immunosuppressant - IrAE | Phase 4 | Unknown | Jun Wang | 40 | 2023-09-01 | 2023-12-20 |
| The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC definitive radiotherapy, induction chemo-immunotherapy, concurrent chemotherapy - Non-small Cell Lung Cancer | Phase 2 | Completed | Sun Yat-sen University | 114 | 2023-07-25 | 2026-08-03 |
| Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma Thymosin Alpha 1 and Anti-PD-1 monoclonal antibody - Melanoma, Immune-related Adverse Event | Phase 2 | Recruiting | Sun Yat-sen University | 55 | 2023-05-30 | 2026-06-12 |
| Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors Thymalfasin, Radiotherapy, PD-1/PD-L1 inhibitor - Advanced Solid Tumor, Refractory Tumor | Phase 2 | Unknown | Second Affiliated Hospital of Soochow University | 60 | 2023-04-01 | 2023-03-30 |
| Protective Effect of Thymosin α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA II) Thymosin Alpha1, 28A-Glycine-28B-L-Arginine-28C-L-Glutamic Acid-28D-L-Alanine-28E-L-Proline-28F-L-Alanine-28G-L-Asparagine-, Blank control - Acute Aortic Syndrome, Aortic Dissection Type A | Not applicable | Completed | Nanjing Medical University | 600 | 2022-07-01 | 2026-09-14 |
| Thymosin α1 Use in Rheumatic Heart Disease Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass Thymosin Alpha1, Blank Control - Rheumatic Heart Disease, Cardiopulmonary Bypass | Not applicable | Unknown | Nanjing Medical University | 200 | 2022-07-01 | 2022-08-04 |
| Zadaxin and HIV-positive Patients With Immune Reconstitution Disorder Zadaxin - HIV-1-infection | Early Phase 1 | Completed | Shanghai Public Health Clinical Center | 20 | 2021-09-01 | 2023-07-18 |
Showing 20 of 54. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (7) · Sepsis (5) · COVID-19 (3) · Colorectal Neoplasms (3) · Hepatitis B, Chronic (3) · Hepatitis C, Chronic (3) · Liver Cirrhosis (3) · Breast Neoplasms (2) · Esophageal Neoplasms (2) · Hematologic Neoplasms (2) · Hepatitis B (2) · Hepatitis C (2) · Lymphopenia (2) · Melanoma (2) · Acquired Immunodeficiency Syndrome (1)
Sun Yat-sen University (8) · Beijing Friendship Hospital (5) · SciClone Pharmaceuticals (5) · Nanjing Medical University (3) · Zhejiang Provincial People's Hospital (3) · sigma-tau i.f.r. S.p.A. (3) · Fudan University (2) · Fakih IVF Fertility Center (1) · First People's Hospital of Hangzhou (1) · Hangzhou Cancer Hospital (1) · Inge Marie Svane (1) · Jia Fan (1) · Jun Wang (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · RenJi Hospital (1)
China (32) · United States (7) · Italy (6) · France (2) · Germany (2) · Puerto Rico (2) · Spain (2) · Bangladesh (1) · Denmark (1) · Greece (1) · Hungary (1) · Poland (1) · Portugal (1) · South Korea (1) · Switzerland (1)
Hong Liu (2) · Hong You, Doctor (2) · Shixiu Wu, MD (2) · Yongshi Jia, MD (2) · Agostino Naso, MD (1) · Andrea Velardi, Prof (1) · Dandan Li, PhD (1) · Eleftherios Mylonakis, MD PhD FIDSA (1) · Guan Xiangdong, M. D (1) · Guan Xiangdong, M.D (1) · Hongyu He (1) · Hongzhou Lu, Ph.D (1) · Hui Liu, Professor (1) · Inge Marie Svane, prof MD (1) · Jingjing Zhao, PhD (1)
PMID 23327199, PMID 35870709, PMID 10741392, PMID 16741252, PMID 17495242, PMID 20194853, PMID 20549321, PMID 22233415, PMID 23045964, PMID 23045967, PMID 23050812, PMID 26094695, PMID 26096650, PMID 26632544, PMID 27257978, PMID 28394330, PMID 31323705, PMID 32817121, PMID 32994239, PMID 33460002, PMID 34408744, PMID 34843068, PMID 35874780, PMID 36056913, PMID 37007743, PMID 38233816, PMID 38356344, PMID 38458816, PMID 39373164, PMID 39814420, PMID 3998766, PMID 40367062, PMID 41749205, PMID 42164588
2004 (1)